Business
Chemed operates hospice services and plumbing and drain-cleaning businesses.
Chemed grew revenue, remained profitable, generated positive free cash flow at a 13.4% operating margin. Revenue grew sharply, while free cash flow and margin conversion softened.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 65.3%OK
- Profitability — Net income declined 12.2% to $265.238M from $301.999MWatch
- Cash flow — Free cash flow declined 11.5% to $325.477M from $367.966MWatch
- Margins — Operating margin contracted 1057 bps to 13.37%Watch
- Accounting — Revenue grew sharply, while free cash flow and margin conversion softenedNote
- Insiders — 1 purchases and 11 salesOK
Where the revenue comes from
Fiscal 2025, as CHEMED CORP reports it. History and quarterly detail are in the app.
- Segment Vitas$1.7B
- Segment Roto Rooter$937.9M
Leadership changes
From CHEMED CORP's own filings, the day they're filed.
- Michael Witzeman · Chief Financial Officer · appointmenteff. 2024-01-01
- David P. Williams On · Chief Financial Officer · departureeff. 2023-12-31
- David P. Willaims · Chief Financial Officer · departureeff. 2023-12-31
Latest filings
- 10-Q · Quarterly report2026-07-31
- 8-K · Company announcement2026-07-28
- 8-K · Company announcement2026-05-19
- 10-Q · Quarterly report2026-04-28
- 8-K · Company announcement2026-04-23
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CHEMED CORP, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.